Restricted accessResearch articleFirst published online 2017-03
Recombinant Parvoviruses Armed to Deliver CXCL4L1 and CXCL10 Are Impaired in Their Antiangiogenic and Antitumoral Effects in a Kaposi Sarcoma Tumor Model Due To the Chemokines' Interference with the Virus Cycle
Application of oncolytic viruses is a valuable option to broaden the armament of anticancer therapies, as these combine specific cytotoxic effects and immune-stimulating properties. The self-replicating H-1 parvovirus (H-1PV) is a prototypical oncolytic virus that, besides targeting tumor cells, also infects endothelial cells, thus combining oncolytic and angiostatic traits. To increase its therapeutic value, H-1PV can be armed with cytokines or chemokines to enhance the immunological response. Some chemokines—more specifically, the CXCR3 ligands CXCL4L1 and CXCL10—combine immune-stimulating properties with angiostatic activity. This study explores the therapeutic value of recombinant parvoviruses carrying CXCL4L1 or CXCL10 transgenes (Chi-H1/CXCL4L1 or Chi-H1/CXCL10, respectively) to inhibit the growth of the human Kaposi sarcoma cell line KS-IMM. KS-IMM cells infected by Chi-H1/CXCL4L1 or Chi-H1/CXCL10 released the corresponding chemokine and showed reduced migratory capacity. Therefore, the antitumoral capacity of Chi-H1/CXCL4L1 or Chi-H1/CXCL10 was tested in mice. Either in vitro infected KS-IMM cells were injected or subcutaneously growing KS-IMM xenografts were treated by peritumoral injections of the different viruses. Surprisingly, the transgenes did not increase the antitumoral effect of natural H-1PV. Further experiments indicated that CXCL4L1 and CXCL10 interfered with the expression of the viral NS1 protein in KS-IMM cells. These results indicate that the outcome of parvovirus-based delivery of CXCR3 ligands might be tumor cell type dependent, and hence its application must be considered carefully.
Get full access to this article
View all access options for this article.
References
1.
BreitbachCJ, ReidT, BurkeJ, et al.Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval. Cytokine Growth Factor Rev, 2010; 21:85–89.
2.
RommelaereJ, GeletnekyK, AngelovaAL, et al.Oncolytic parvoviruses as cancer therapeutics. Cytokine Growth Factor Rev, 2010; 21:185–195.
3.
VollmersEM, TattersallP. Distinct host cell fates for human malignant melanoma targeted by oncolytic rodent parvoviruses. Virology, 2013; 446:37–48.
4.
WollmannG, TattersallP, van den PolAN. Targeting human glioblastoma cells: comparison of nine viruses with oncolytic potential. J Virol, 2005; 79:6005–6022.
5.
GeletnekyK, HuesingJ, RommelaereJ, et al.Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol. BMC Cancer, 2012; 12:99.
6.
NueschJP, LacroixJ, MarchiniA, et al.Molecular pathways: rodent parvoviruses—mechanisms of oncolysis and prospects for clinical cancer treatment. Clin Cancer Res, 2012; 18:3516–3523.
7.
LavieM, StruyfS, Stroh-DegeA, et al.Capacity of wild-type and chemokine-armed parvovirus H-1PV for inhibiting neo-angiogenesis. Virology, 2013; 447:221–232.
8.
GieseNA, RaykovZ, DeMartinoL, et al.Suppression of metastatic hemangiosarcoma by a parvovirus MVMp vector transducing the IP-10 chemokine into immunocompetent mice. Cancer Gene Ther, 2002; 9:432–442.
9.
HaagA, MentenP, Van DammeJ, et al.Highly efficient transduction and expression of cytokine genes in human tumor cells by means of autonomous parvovirus vectors; generation of antitumor responses in recipient mice. Hum Gene Ther, 2000; 11:597–609.
10.
WetzelK, StruyfS, Van DammeJ, et al.MCP-3 (CCL7) delivered by parvovirus MVMp reduces tumorigenicity of mouse melanoma cells through activation of T lymphocytes and NK cells. Int J Cancer, 2007; 120:1364–1371.
11.
EnderlinM, KleinmannEV, StruyfS, et al.TNF-alpha and the IFN-gamma-inducible protein 10 (IP-10/CXCL-10) delivered by parvoviral vectors act in synergy to induce antitumor effects in mouse glioblastoma. Cancer Gene Ther, 2009; 16:149–160.
12.
DempeS, LavieM, StruyfS, et al.Antitumoral activity of parvovirus-mediated IL-2 and MCP-3/CCL7 delivery into human pancreatic cancer: implication of leucocyte recruitment. Cancer Immunol Immunother, 2012; 61:2113–2123.
13.
LasagniL, FrancalanciM, AnnunziatoF, et al.An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med, 2003; 197:1537–1549.
14.
LoetscherM, GerberB, LoetscherP, et al.Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes. J Exp Med, 1996; 184:963–969.
15.
LiY, JinY, ChenH, et al.Suppression of tumor growth by viral vector-mediated gene transfer of N-terminal truncated platelet factor 4. Cancer Biother Radiopharm, 2003; 18:829–840.
16.
LiuTC, ZhangT, FukuharaH, et al.Oncolytic HSV armed with platelet factor 4, an antiangiogenic agent, shows enhanced efficacy. Mol Ther, 2006; 14:789–797.
17.
TanakaT, ManomeY, WenP, et al.Viral vector-mediated transduction of a modified platelet factor 4 cDNA inhibits angiogenesis and tumor growth. Nat Med, 1997; 3:437–442.
18.
StruyfS, BurdickMD, ProostP, et al.Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis. Circ Res, 2004; 95:855–857.
19.
StruyfS, BurdickMD, PeetersE, et al.Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis. Cancer Res, 2007; 67:5940–5948.
20.
AlbiniA, PaglieriI, OrengoG, et al.The beta-core fragment of human chorionic gonadotrophin inhibits growth of Kaposi's sarcoma-derived cells and a new immortalized Kaposi's sarcoma cell line. AIDS, 1997; 11:713–721.
21.
TattersallP, BrattonJ. Reciprocal productive and restrictive virus-cell interactions of immunosuppressive and prototype strains of minute virus of mice. J Virol, 1983; 46:944–955.
22.
Van RaemdonckK, GouwyM, LepersSA, et al.CXCL4L1 and CXCL4 signaling in human lymphatic and microvascular endothelial cells and activated lymphocytes: involvement of mitogen-activated protein (MAP) kinases, Src and p70S6 kinase. Angiogenesis, 2014; 17:631–640.
23.
Van RaemdonckK, BerghmansN, VanheuleV, et al.Angiostatic, tumor inflammatory and anti-tumor effects of CXCL4(47-70) and CXCL4L1(47-70) in an EGF-dependent breast cancer model. Oncotarget, 2014; 5:10916–10933.
24.
LivakKJ, SchmittgenTD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 2001; 25:402–408.
25.
StruyfS, SalogniL, BurdickMD, et al.Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3. Blood, 2011; 117:480–488.
26.
KellyE, RussellSJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther, 2007; 15:651–659.
27.
KaufmanHL, AmatrudaT, ReidT, et al.Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional Phase II study. J Immunother Cancer, 2016; 4:12.
28.
Van RaemdonckK, Van den SteenPE, LiekensS, et al.CXCR3 ligands in disease and therapy. Cytokine Growth Factor Rev, 2015; 26:311–327.
WongLM, MyersSJ, TsouCL, et al.Organization and differential expression of the human monocyte chemoattractant protein 1 receptor gene. Evidence for the role of the carboxyl-terminal tail in receptor trafficking. J Biol Chem, 1997; 272:1038–1045.
31.
YuCR, PedenKW, ZaitsevaMB, et al.CCR9A and CCR9B: two receptors for the chemokine CCL25/TECK/Ck beta-15 that differ in their sensitivities to ligand. J Immunol, 2000; 164:1293–1305.
32.
WuQ, DhirR, WellsA. Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion. Mol Cancer, 2012; 11:3.
33.
LiY, ReaderJC, MaX, et al.Divergent roles of CXCR3 isoforms in promoting cancer stem-like cell survival and metastasis. Breast Cancer Res Treat, 2015; 149:403–415.
34.
De SilvaN, AtkinsH, KirnDH, et al.Double trouble for tumours: exploiting the tumour microenvironment to enhance anticancer effect of oncolytic viruses. Cytokine Growth Factor Rev, 2010; 21:135–141.
